Perioperative Intravenous Lidocaine in Liver Surgery

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized double blinded placebo-controlled study, conducted in Lund, Sweden. Patients will be randomized in two groups, with a ratio of 1:1. The experimental arm will receive intravenous Lidocaine perioperatively, and the Control arm will receive placebo, i.e. normal Saline. Postoperative both arms will get routine pain Control with PCA, Patient Controlled Analgesia with an intravenous Oxycodone-infusion. Outcome-measures will include patients pain intensity scoring, and opioid consumption.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University Hospital
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Age 18 yy

• Patient planned for minor hepatectomy

• Signed informed consent

Exclusion Criteria:

• Pregnancy

• Cirrosis

• ASA>3

• Elevated liver enzymes

• AV-block >1, without pacemaker

• WHO class >2

• Allergy against Lidocain or other amid-type local anasthesia

• Heart failure

• Epilepsy

• Treatment with class III anti-arythimic medication

• Preoperative ongoing opioid usage

• Use of : Erythromycin, clarithromycin, Fluvoxamine, Cimetidine, ciprofloxacin, antivirala-HIV-läkemedel or imidazol the week before surgery.